Anticholinergic burden and constipation

A bowel symptom needs its own description

Constipation is more informative when described than when reduced to a checkbox. A person may report hard stools, painful passage, straining, incomplete emptying or a change from their usual pattern. The NIDDK guidance recognizes several symptom dimensions, which helps explain why bowel frequency alone is an incomplete outcome.

Anticholinergic exposure can be relevant to that history, but a medication score is not a constipation assessment. It does not measure stool characteristics, abdominal symptoms, duration or the effect on eating and daily activity. Those details determine what clinical question the medication evidence is being asked to support.

The medication mechanism is plausible, but causation still needs assessment

Antimuscarinic effects can reduce gastrointestinal motility. This concern is reflected in the oxybutynin extended-release prescribing information, which includes gastrointestinal precautions and constipation among relevant adverse effects. That product-specific evidence is more precise than assuming every medication with a nonzero score has the same effect in every person.

A plausible mechanism does not prove that the medicine explains a current symptom. Constipation may have several contributors at once. A person can also have constipation for reasons unrelated to an anticholinergic exposure. The clinical assessment should preserve both possibilities.

Other medicines can matter even if the burden category is low

The NIDDK list of medication contributors extends beyond anticholinergics. This is a useful reminder that an anticholinergic directory covers one evidence domain. A low or absent classification cannot clear the entire regimen of constipation-related concerns.

For the same reason, a symptom review should include supplements and nonprescription products. Their relevance depends on the actual ingredients and use, not on whether they appear in the electronic prescription list. The medication history should establish exposure before any contribution is assumed.

Timing provides information a source score cannot

Document when the bowel pattern changed relative to medication starts, dose changes, new formulations and changes in actual use. An occasional medicine taken repeatedly during a difficult week may have a different exposure pattern from the same order on a stable list. The published category alone will not show that difference.

Also distinguish the order of events. A medicine may have been added because of symptoms associated with an illness that also changed bowel function. If the illness, diet, activity and regimen all changed together, assigning causation to the medication score alone would be unjustified.

A consistent symptom record can help the treating team assess the course. It should describe the bowel outcome directly rather than assume that a lower burden number means the symptom improved.

Read the medication-specific evidence before the class explanation

In UnifiedACB, the source table shows what each public source reported for the selected medication. The original label and version help determine whether the record matches the intended product. A formulation note may be especially relevant when the product has specific administration or gastrointestinal considerations.

Class-level context can explain why an antimuscarinic effect is worth considering. It should not be presented as proof that all members have identical clinical effects. Drug-specific warnings and qualifications need their own source support rather than being invented to make profiles appear more detailed.

Supplemental geriatric criteria may add another reason to review the regimen, but they do not supply a constipation severity score. The explanation should keep the bowel symptom, source classification and clinical criterion as separate pieces of information.

Why treating a number is an incomplete response

The goal of review is a clinically meaningful outcome, such as improved comfort or bowel function, while preserving needed treatment. A burden score does not choose a bowel regimen, assess the appropriateness of adding another medicine or decide whether an existing treatment can be changed safely.

If a treating team modifies care, follow-up should examine the actual symptom and any consequences for the original indication. A symptom response can provide useful information, but simultaneous changes can make attribution difficult. Documentation should reflect that uncertainty instead of claiming that the numerical change itself caused improvement.

A newly added bowel treatment should also be recorded as part of the evolving regimen. Its addition does not prove which earlier medicine caused constipation. The chronology can reveal a question about symptom management, but the clinical interpretation still requires the actual findings and the benefit of each treatment.

Symptoms that need direct clinical attention

Constipation accompanied by persistent abdominal pain, vomiting, inability to pass gas or bleeding should not be explained away by a medication badge. NIDDK identifies concerning accompanying symptoms that warrant prompt assessment. The availability of an anticholinergic classification does not rule out another gastrointestinal problem.

For a routine review, bring a clear symptom description and complete medication list to the clinician or pharmacist. The directory can help formulate focused questions about exposure. It cannot determine the cause or appropriate treatment from a source category alone.

The central interpretation

Anticholinergic evidence is useful when it adds a specific, source-supported medication question to a bowel assessment. Keep the symptom pattern and timeline primary, review other possible contributors, and judge any intervention by clinical outcomes rather than by whether the score became smaller.

References

1. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71:2052-2081. Source
2. Vennard O, Stewart C, Tolia M, Soiza RL, Myint PK. Anticholinergic Medication Burden Scales: A Systematic Review. J Am Geriatr Soc. 2026;74(6):1771-1784. Source
3. American Geriatrics Society Beers Criteria Alternatives Panel. Alternative Treatments to Selected Medications in the 2023 AGS Beers Criteria. J Am Geriatr Soc. 2025;73:2657-2677. Source
4. Fox C, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604-615. Source
5. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209-220. doi:10.1111/bcp.12617. Source
6. Egberts A, et al. Anticholinergic Drug Burden and Delirium: A Systematic Review. J Am Med Dir Assoc. 2021;22:65-73.e4. Source
7. National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Constipation. Official health information. Source
8. DailyMed. Oxybutynin chloride extended-release tablets. Official prescribing information; set ID 7d2332b4-9e48-4bb2-a2c3-75e16e1d455b. Source
9. UnifiedACB. Preserved public source-observation dataset, v3.0 RC12 final; inspected for this editorial revision. Source

Disclosure

Funding: None. Conflict of interest: None declared for the UnifiedACB educational project.

Educational evidence summary. This content does not provide patient-specific medical advice and does not replace clinical judgment, medication reconciliation, or prescribing guidance.